PRODUCT NAME

Mosunetuzumab Biosimilar - Research Grade

SPECIES REACTIVITY

Human

HOST

SPECIFICITY

Detects human CD3/CD20. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Mosunetuzumab. This product is for research use only.

PURIFICATION METHOD

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

ANTIGEN DISTRIBUTION

IMMUNOGEN

CONCENTRATION

FORMULATION

Sterile, preservative-free, solution in PBS. BSA and Azide free.

PURITY

>95% by SDS-PAGE

ENDOTOXIN

≤ 1.0 EU/mg as determined by the LAL method

AGGRIGATION

STORAGE CONDITION

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

TARGET

CD3e/CD20

CLONE

SYNONYMS

BACKGROUND

ichorbio’s Mosunetuzumab biosimilar is a bispecific, humanized monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 bispecific monoclonal antibody BTCT4465A contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, BTCT4465A binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells.

UNIPROT

PATHOGEN TEST

APPLICATIONS

Functional Assays

APPLICATION NOTES

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

USAGE

Products are for research use only. Not for use in diagnostic or therapeutic procedures.